Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease (or non-alcoholic steatohepatitis, NASH), cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea. Its lead product is obeticholic acid, OCA, also known as 6-ethyl-chenodeoxycholic acid or INT-747, marketed as Ocaliva. OCA is a potent first-in-class farnesoid X receptor (FXR) agonist. Ocaliva is approved in the US and the EU for use in primary biliary cholangitis.


Type
Public
HQ
New York, US
Founded
2002
Size (employees)
456 (est)
Intercept Pharmaceuticals was founded in 2002 and is headquartered in New York, US
Report incorrect company information

Key People/Management at Intercept Pharmaceuticals

Mark Pruzanski

Mark Pruzanski

Chief Executive Officer & President
Luciano Adorini

Luciano Adorini

Chief Scientific Officer

Intercept Pharmaceuticals Office Locations

Intercept Pharmaceuticals has offices in Lisboa, Milano, Wien, Zürich and in 8 other locations
New York, US (HQ)
10 Hudson Yards
Wien, AT
1 Fleischmarkt
Mississauga, CA
90 Burnhamthorpe Rd W
Kongens Lyngby, DK
10C Lyngby Hovedgade
Paris, FR
21 Boulevard Haussmann
München, DE
52 Rosenheimer Str.
Show all (12)
Report incorrect company information

Intercept Pharmaceuticals Financials and Metrics

Intercept Pharmaceuticals Financials

Intercept Pharmaceuticals's revenue was reported to be $130.96 m in FY, 2017
USD

Revenue (Q1, 2018)

36 m

Gross profit (Q1, 2018)

35.7 m

Gross profit margin (Q1, 2018), %

99.2%

Net income (Q1, 2018)

(81.6 m)

EBIT (Q1, 2018)

(75.5 m)

Market capitalization (25-May-2018)

2.1 b

Closing share price (25-May-2018)

71.1

Cash (31-Mar-2018)

48.9 m

EV

2.4 b
Intercept Pharmaceuticals's current market capitalization is $2.1 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

25 m131 m

Cost of goods sold

1.4 m

Gross profit

129.6 m

Gross profit Margin, %

99%
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

5.5 m5.2 m21 m30.9 m36 m

Cost of goods sold

97 k279 k280 k

Gross profit

21 m30.6 m35.7 m

Gross profit Margin, %

100%99%99%
Annual
usdY, 2009Y, 2010Y, 2011Y, 2012Y, 2013Y, 2014Y, 2015FY, 2016FY, 2017

Cash

4.4 m15.4 m17.7 m45.5 m13.4 m20 m32.7 m43.7 m70 m

Accounts Receivable

9.1 m16.5 m

Inventories

2.7 m6.1 m13.6 m2.3 m3.5 m

Current Assets

147.6 m245.8 m641.7 m707.9 m448.3 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

33.5 m11.2 m45 m18.1 m104.4 m88.3 m72.4 m49.2 m51.7 m105.2 m67 m62 m48.9 m

Accounts Receivable

10.6 m13.2 m16.9 m

Inventories

2.1 m2.7 m7.9 m

Current Assets

158.4 m138.9 m306.6 m279.1 m410.4 m741 m702.5 m574.9 m505.3 m794.6 m635 m578.6 m363.8 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(67.8 m)(283.2 m)(226.4 m)(412.8 m)(360.4 m)

Depreciation and Amortization

105.7 k442.8 k1.7 m3.8 m4.6 m

Inventories

(1.7 m)(2.3 m)(1.2 m)

Accounts Payable

7.3 m208 k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(31.7 m)(257.7 m)33.5 m(35.8 m)(39.4 m)(47.9 m)(50.9 m)(126.7 m)(77.3 m)(88.8 m)(89.9 m)(81.6 m)

Depreciation and Amortization

1.3 m

Inventories

2.1 m(4.5 m)

Accounts Payable

(3.7 m)
USDY, 2018

EV/EBIT

-32 x

EV/CFO

-27.2 x

Financial Leverage

-7.5 x
Show all financial metrics
Report incorrect company information

Intercept Pharmaceuticals News and Updates

Report incorrect company information